Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLS NASDAQ:CRDF NASDAQ:FBRX NASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.89-3.0%$2.47$1.10▼$3.35$160.64M3.03214,325 shs149,395 shsCRDFCardiff Oncology$2.05-1.4%$2.90$1.90▼$5.64$136.39M1.281.41 million shs616,958 shsFBRXForte Biosciences$10.56+1.0%$10.91$4.11▼$28.68$131.26M2.6963,586 shs42,025 shsRLMDRelmada Therapeutics$1.59+4.6%$0.79$0.24▼$3.98$52.77M0.741.23 million shs425,453 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis-2.30%+13.31%+12.03%+124.06%+31.28%CRDFCardiff Oncology+1.96%-2.35%-14.40%-45.41%-9.96%FBRXForte Biosciences-3.95%-4.56%-2.79%-13.48%+47.53%RLMDRelmada Therapeutics-5.59%+10.95%+158.50%+117.08%-49.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$2.89-3.0%$2.47$1.10▼$3.35$160.64M3.03214,325 shs149,395 shsCRDFCardiff Oncology$2.05-1.4%$2.90$1.90▼$5.64$136.39M1.281.41 million shs616,958 shsFBRXForte Biosciences$10.56+1.0%$10.91$4.11▼$28.68$131.26M2.6963,586 shs42,025 shsRLMDRelmada Therapeutics$1.59+4.6%$0.79$0.24▼$3.98$52.77M0.741.23 million shs425,453 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis-2.30%+13.31%+12.03%+124.06%+31.28%CRDFCardiff Oncology+1.96%-2.35%-14.40%-45.41%-9.96%FBRXForte Biosciences-3.95%-4.56%-2.79%-13.48%+47.53%RLMDRelmada Therapeutics-5.59%+10.95%+158.50%+117.08%-49.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$4.0036.05% UpsideCRDFCardiff Oncology 2.80Moderate Buy$10.63417.03% UpsideFBRXForte Biosciences 3.00Buy$68.00543.33% UpsideRLMDRelmada Therapeutics 2.25Hold$5.00223.62% UpsideCurrent Analyst Ratings BreakdownLatest RLMD, CLLS, CRDF, and FBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$61.008/6/2025CRDFCardiff OncologyHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $10.007/8/2025CRDFCardiff OncologyLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$19.006/24/2025CRDFCardiff OncologyJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold$3.506/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$61.006/18/2025CRDFCardiff OncologyWilliam BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$49.22M3.32N/AN/A$2.36 per share1.25CRDFCardiff Oncology$680K201.06N/AN/A$1.86 per share1.10FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/ARLMDRelmada TherapeuticsN/AN/AN/AN/A$1.18 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$36.76M-$0.82N/AN/AN/A-100.69%-68.05%-21.53%11/3/2025 (Estimated)CRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)RLMDRelmada Therapeutics-$79.98M-$2.22N/AN/AN/AN/A-223.17%-180.41%11/6/2025 (Estimated)Latest RLMD, CLLS, CRDF, and FBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/7/2025Q2 2025RLMDRelmada Therapeutics-$0.25-$0.30-$0.05-$0.30N/AN/A8/4/2025Q2 2025CLLSCellectis-$0.15-$0.24-$0.09-$0.24$10.07 million$18.19 million7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.581.381.38CRDFCardiff OncologyN/A4.424.42FBRXForte BiosciencesN/A11.7411.74RLMDRelmada TherapeuticsN/A4.114.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%CRDFCardiff Oncology16.29%FBRXForte Biosciences77.63%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%CRDFCardiff Oncology7.70%FBRXForte Biosciences5.90%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableRLMDRelmada Therapeutics1033.19 million26.32 millionOptionableRLMD, CLLS, CRDF, and FBRX HeadlinesRecent News About These CompaniesRelmada Therapeutics CEO remains ‘optimistic’ about company’s futureSeptember 10 at 3:29 PM | msn.comRelmada Therapeutics Provides Transformational Update and Strategic Outlook in Shareholder LetterSeptember 10 at 7:31 AM | quiverquant.comQRelmada Issues Mid-Year CEO Letter to ShareholdersSeptember 10 at 7:15 AM | globenewswire.comExclusive: Relmada CEO says his recent buy reflects ’significant undervaluation’September 4, 2025 | finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer StudySeptember 2, 2025 | finance.yahoo.comRelmada Therapeutics (NASDAQ:RLMD) Stock Price Up 44.5% - Still a Buy?September 2, 2025 | americanbankingnews.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | msn.comRelmada Therapeutics Reports Promising Phase 2 Study ResultsAugust 11, 2025 | theglobeandmail.comRelmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comRelmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025July 31, 2025 | globenewswire.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | finance.yahoo.comRelmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01July 15, 2025 | globenewswire.comRelmada terminates license agreement for troubled phase 3 depression assetJuly 11, 2025 | fiercebiotech.comFDIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of DirectorsJuly 9, 2025 | globenewswire.comRelmada Therapeutics Inc News (RLMD) - Investing.comJuly 2, 2025 | investing.comRLMD Relmada Therapeutics, Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comRelmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With LossesJune 28, 2025 | uk.finance.yahoo.comRelmada Therapeutics, Inc. (RLMD) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRLMD - Relmada Therapeutics Inc Executives - MorningstarJune 24, 2025 | morningstar.comMRelmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder CancerJune 17, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRLMD, CLLS, CRDF, and FBRX Company DescriptionsCellectis NASDAQ:CLLS$2.89 -0.09 (-3.02%) Closing price 04:00 PM EasternExtended Trading$2.89 0.00 (0.00%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Cardiff Oncology NASDAQ:CRDF$2.05 -0.03 (-1.44%) Closing price 04:00 PM EasternExtended Trading$2.08 +0.04 (+1.71%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Forte Biosciences NASDAQ:FBRX$10.56 +0.10 (+0.96%) Closing price 04:00 PM EasternExtended Trading$10.53 -0.03 (-0.25%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Relmada Therapeutics NASDAQ:RLMD$1.59 +0.07 (+4.61%) Closing price 04:00 PM EasternExtended Trading$1.53 -0.06 (-3.77%) As of 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
